HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: a 24-week randomized, double-blind, placebo-controlled trial.

AbstractOBJECTIVE:
Down syndrome (DS) patients share certain neuropathological features with Alzheimer disease patients. A randomized, double-blind, placebo-controlled study was performed to investigate the efficacy and safety of donepezil, an Alzheimer disease drug, for DS patients.
METHOD:
Twenty-one DS patients with severe cognitive impairment were assigned to take donepezil (3 mg daily) or a placebo for 24 weeks, and evaluated for activities in daily lives by concisely modified International Classification of Functioning, Disability and Health (ICF) scaling system.
RESULTS:
ICF scores significantly increased without any adverse effects in the donepezil group in comparison to those in the placebo control. Among the individual functions tested, there was a dramatic improvement in the global mental functions and in specific mental functions.
CONCLUSIONS:
Donepezil may effectively and safely improve overall functioning of DS patients with severe cognitive impairment.
AuthorsTatsuro Kondoh, Atsushi Kanno, Hiroshi Itoh, Mikiro Nakashima, Ryoko Honda, Michio Kojima, Mitsuru Noguchi, Hideyuki Nakane, Hidetsugu Nozaki, Hitoshi Sasaki, Toshiro Nagai, Rika Kosaki, Naoko Kakee, Torayuki Okuyama, Masafumi Fukuda, Masayuki Ikeda, Yoshisada Shibata, Hiroyuki Moriuchi
JournalInternational journal of psychiatry in medicine (Int J Psychiatry Med) Vol. 41 Issue 1 Pg. 71-89 ( 2011) ISSN: 0091-2174 [Print] United States
PMID21495523 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Indans
  • Nootropic Agents
  • Piperidines
  • Donepezil
Topics
  • Activities of Daily Living
  • Adult
  • Cognition Disorders (complications, drug therapy)
  • Donepezil
  • Double-Blind Method
  • Down Syndrome (complications, drug therapy)
  • Female
  • Humans
  • Indans (therapeutic use)
  • Middle Aged
  • Neuropsychological Tests
  • Nootropic Agents (therapeutic use)
  • Piperidines (therapeutic use)
  • Quality of Life
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: